You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. An Augmented Reality Sandbox for use in Early Elementary STEM Instruction

    SBC: Parametric Studio, Inc.            Topic: 91990020R0007

    This project will fully develop NEWTON-AR, an augmented reality (AR) application-based engineering, computer science, and STEM puzzle game for children in kindergarten to grade three. Intended for use in classrooms, after-school programs, and at home, NEWTON-AR will combine AR, engineering, simulation, making, and programming into a sandbox game where students create, modify, simulate, prototype, ...

    SBIR Phase II 2020 Department of EducationInstitute of Education Sciences
  2. Discovery of Novel Pharmaceutical Agents for Skeletal Muscle Atrophy

    SBC: EMMYON, INC.            Topic: NIAMS

    PROJECT SUMMARY / ABSTRACT Skeletal muscle atrophy diminishes the health and quality of life of tens of millions of people in the US alone. Frequent causes of muscle atrophy (which often co-exist in the same patient) include aging, malnutrition, muscle disuse, critical illness, certain medications, and a broad range of chronic illnesses including cancer, heart failure, COPD, diabetes, renal failur ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Improving The Reproducibility and Genetic Stability of IPSC and Differentiated Cells Through Oncogene-Free Reprogramming and Fully Human Growth Factors

    SBC: Cellular Engineering Technologies, Inc.            Topic: 400

    Cellular Engineering Technologies (CET) has submitted this proposal in response to RFA-GM- 19-001. CET has proposed a direct Phase II SBIR application to create more reproducible human induced pluripotent stem cells (iPSCs) and create methods for growing, maintaining, and authenticating iPSCs. A major challenge in iPSC manufacturing and subsequent differentiation is the emergence of genetic instab ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.

    SBC: VIEWPOINT MOLECULAR TARGETING, LLC            Topic: NCI

    Melanoma incidence in the United States is growing rapidly. Surgery combined with radiation can be curative at early stages but, metastatic melanoma is usually fatal. Since 2011, targeted MAPKi and immunotherapies have improved outcomes, but low response rates, acquired resistance, and adverse events limit quality of life for these patients (5-yr. survival andlt;25%). Under predicate Randamp;D, Vi ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Micro-Mechanical Insertion Tool with Intraoperative Real-Time Electrophysiological Sensing Control for Cochlear Implantation

    SBC: iotaMotion, Inc.            Topic: NIDCD

    Project Summary/Abstract. One of the more recent goals of cochlear implant (CI) surgery is the preservation of residual hearing to improve overall patient outcomes. Unfortunately, up to 50% of patients experience delayed residual hearing loss following cochlear implant surgery, resulting in a diminished quality of life. To address this issue, iotaMotion is developing an insertion system to assist ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors.

    SBC: VIEWPOINT MOLECULAR TARGETING, LLC            Topic: NCI

    Neuroendocrine tumors (NET) are enigmatic malignancies, with an increasing incidence and poor outcomes (5-yr survival andlt;30%). Recently, peptide-receptor radionuclide therapy (PRRT) using [177Lu]DOTATATE beta(b)-particle treatment (LutatheraÔ) improved survival vs standard of care and was FDA approved. However, objective tumor responses were low (18%) in the Phase 3 trial. Nonetheless, Lutathe ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Mol: An Interactive Learning Platform to Address Difficult Concepts in Organic Chemistry

    SBC: Substrate Interactive, Inc.            Topic: 500

    Abstract Concepts of organic chemistry are central to medicine and pharmacology. However, organic chemistry represents a significant hurdle for science, technology, engineering, and mathematics students in pre-health tracks. Low exam scores and high failure rates result from the enormous amount of information, complex chemical structures and dynamics, and processes requiring creativity and spatial ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Artificial intelligence-enabled, real-time communication software for optimizing clinical decision making during the allocation, procurement, and transplantation of donated organs

    SBC: Healthtech Solutions, Inc.            Topic: NLM

    Project Abstract for HealthTech Solutions Kidney transplantation is a clinically effective and cost-effective treatment for patients suffering from end-stage renal disease (ESRD) and diabetes. Twenty-two patients die each day waiting for a transplant and 30% of all deaths in the US could be prevented by organ transplant. Despite the obvious clinical and cost-effective advantages of kidney transpla ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. An Automated Patient Chart Error Detection System for Radiation Therapy

    SBC: Infondrian LLC            Topic: 101

    Project Summary/Abstract Every year, approximately 1,200 severe mistreatments happen in radiation therapy. Radiation therapy lawsuits rank in the top third of all medical specialties with an average of $313,000 per claim settled or litigated. The current method for detecting treatment errors is by a weekly patient chart check, where each treatment record is manually reviewed on a weekly basis. Thi ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma

    SBC: VIEWPOINT MOLECULAR TARGETING, LLC            Topic: 102

    SIGNIFICANCE: Melanoma incidence is rising faster than any other cancer and metastatic melanoma is typically fatal. Responses to targeted and immunotherapies can be remarkable, but low response rates, acquired resistance, and adverse side effects limit long-term quality of life for these patients. The overall response rate to all therapies remains dismally near 50% and the 5-year survival is andlt ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government